⚕ GalenOps CRO console
← SITE002 (USA)

SITE002-0025

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE002 (USA) (Dr. Nolan) · consented 2022-03-18
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-07 (study day 8); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-05-26 (study day 57); relationship: N

severe serious assessed 2026-08-18

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-07-27 (study day 119); relationship: N; serious criteria: hospitalization

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 133); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 138); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 266); relationship: Y

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 324); relationship: N

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 345); relationship: Y

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.